Incyte Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?
INCYTE CORP has three approved drugs.
There are twenty-four US patents protecting INCYTE CORP drugs.
There are three hundred and ninety-six patent family members on INCYTE CORP drugs in fifty countries and forty-one supplementary protection certificates in eighteen countries.
Drugs and US Patents for Incyte Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | 11,628,162 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-001 | Nov 16, 2011 | RX | Yes | No | 10,016,429*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 2426129 | ⤷ Try a Trial |
Denmark | 3495367 | ⤷ Try a Trial |
Japan | 2023027344 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2861595 | CA 2021 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1535 20210329 |
2455382 | CR 2017 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: EU/1/12/773/001-016/C(2015)1740 20150313 |
1966202 | 145 1-2013 | Slovakia | ⤷ Try a Trial | FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US; |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.